Prices are falling for the popular obesity treatments Wegovy and Zepbound, but steady access to the drugs remains challenging ...

Do those on Zepbound have to switch to Wegovy after Caremark drops Zepbound from preferred coverage? What options are there?

Zepbound growth has outpaced Wegovy in recent months, and sales quadrupled to $2.31 billion in the first three months of this year compared to the same period of 2024, while Mounjaro more than ...

Prediction: Eli Lilly's Newest ... Zepbound revenue soared from $175.8 million to $1.9 billion, while Mounjaro sales jumped 60% to $3.5 billion. Both drugs have the same active ingredient ...

For the quarter ended March 31, Mounjaro was Lilly's largest source of revenue, generating $1.8 billion. Moreover, Zepbound reported approximately $500 million in sales -- putting it on a run rate ...

Eli Lilly has revised its revenue forecast for 2024 after seeing weaker-than-expected growth for its diabetes and obesity therapies – but still said sales rose around a third over the prior year.

Eli Lilly's blockbuster weight loss drug Zepbound and diabetes treatment Mounjaro posted weaker-than-expected sales for the third quarter, even as both medicines have largely recovered from ...

Sales of Eli Lilly’s (LLY) blockbuster weight-loss drug Zepbound surged in the fourth quarter despite missing the company’s initial sales expectations. Zepbound sales reached $1.9 billion in ...

Eli Lilly and Co.'s second-quarter earnings surpassed Wall Street estimates as sales of its blockbuster weight-loss drugs soared. "Mounjaro, Zepbound and Verzenio led our strong financial ...